15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL
- PMID: 16027765
- PMCID: PMC1163271
- DOI: 10.4088/pcc.v07n0305
15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL
Abstract
Background: Bupropion has been available in the United States since 1989. Initially a thrice-daily immediate-release formulation, a twice-daily sustained-release formulation followed in 1996, and, in August 2003, a once-daily extended-release formulation was introduced. On the 15th anniversary of its introduction, we undertook a review of the background/history, mechanism of action, formulations, and clinical profile of bupropion.
Data sources: Major efficacy trials and other reports were obtained and reviewed from MEDLINE searches, review of abstracts from professional meetings, and the bupropion SR manufacturer's databases. Searches of English-language articles were conducted from June 2003 through August 2004. No time limit was specified in the searches, which were conducted using the search terms bupropion, bupropion SR, and bupropion XL.
Data synthesis: Bupropion inhibits the re-uptake of norepinephrine and dopamine neurotransmission without any significant direct effects on serotonin neurotransmission. Bupropion is an effective antidepressant with efficacy comparable to selective serotonin reuptake inhibitors and other antidepressants. It is well tolerated in short-and longer-term treatment. Headache, dry mouth, nausea, insomnia, constipation, and dizziness are the most common adverse events. Seizure and allergic reactions are medically important adverse events associated with bupropion and are reported rarely. Among all the newer antidepressants in the United States, bupropion appears to have among the lowest incidence of sexual dysfunction, weight gain, and somnolence. Although not U.S. Food and Drug Administration approved for these indications, bupropion has also been used as an adjunctive treatment to reverse antidepressant-induced sexual dysfunction and to augment anti-depressant efficacy in partial responders and non-responders to other agents.
Conclusion: Bupropion has played and will continue to play an important role as a treatment for major depressive disorder in adults, as well as for other related disorders.
Figures
Similar articles
-
Tolerance of Bupropion SR After Delayed-Onset Urticaria and Angioedema Associated With Bupropion XL.Case Rep Psychiatry. 2024 Oct 23;2024:6638911. doi: 10.1155/2024/6638911. eCollection 2024. Case Rep Psychiatry. 2024. PMID: 39478846 Free PMC article.
-
A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166. doi: 10.4088/pcc.v06n0403. Prim Care Companion J Clin Psychiatry. 2004. PMID: 15361919 Free PMC article.
-
Spotlight on bupropion in major depressive disorder.CNS Drugs. 2008;22(7):613-7. doi: 10.2165/00023210-200822070-00006. CNS Drugs. 2008. PMID: 18547129 Review.
-
Bupropion sustained release: side effect profile.J Clin Psychiatry. 1998;59 Suppl 4:32-6. J Clin Psychiatry. 1998. PMID: 9554319 Review.
-
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.Clin Ther. 2005 Nov;27(11):1685-95. doi: 10.1016/j.clinthera.2005.11.011. Clin Ther. 2005. PMID: 16368442 Review.
Cited by
-
Tolerance of Bupropion SR After Delayed-Onset Urticaria and Angioedema Associated With Bupropion XL.Case Rep Psychiatry. 2024 Oct 23;2024:6638911. doi: 10.1155/2024/6638911. eCollection 2024. Case Rep Psychiatry. 2024. PMID: 39478846 Free PMC article.
-
Antidepressant nonadherence and sexual dysfunction among young adult males: the cross-sectional YAMAN study.World J Urol. 2024 May 6;42(1):295. doi: 10.1007/s00345-024-05003-3. World J Urol. 2024. PMID: 38709300
-
The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials.Diabetol Metab Syndr. 2024 Apr 24;16(1):93. doi: 10.1186/s13098-024-01319-7. Diabetol Metab Syndr. 2024. PMID: 38658994 Free PMC article.
-
Cannabidiol as a potential cessation therapeutic: Effects on intravenous nicotine self-administration and withdrawal symptoms in mice.Neuropharmacology. 2024 Mar 15;246:109833. doi: 10.1016/j.neuropharm.2023.109833. Epub 2024 Jan 3. Neuropharmacology. 2024. PMID: 38176534 Free PMC article.
-
Diving with psychotropic medication: review of the literature and clinical considerations.Diving Hyperb Med. 2023 Sep 30;53(3):259-267. doi: 10.28920/dhm53.3.259-267. Diving Hyperb Med. 2023. PMID: 37718301 Free PMC article. Review.
References
-
- Soroko FE, Maxwell RA. The pharmacologic basis for therapeutic interest in bupropion. J Clin Psychiatry. 1983 44(sec 2). 67–73. - PubMed
-
- Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press. 2000
-
- Wellbutrin (bupropion) tablets, Wellbutrin SR (bupropion), and Wellbutrin XL (bupropion). Physician's Desk Reference. Montvale, NJ: Thomson PDR. 2005 1655–1659. 1659,–1663. 1663–1668.
-
- Dunner DL, Zisook S, and Billow AA. et al. A prospective safety surveillance study for bupropion sustained release in the treatment of depression. J Clin Psychiatry. 1998 59:366–373. - PubMed
-
- Johnston JA, Fiedler-Kelly J, and Glover ED. et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained-release for smoking cessation. Nicotine Tob Res. 2001 3:131–140. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials